@article{PAR00014891,
  title = {{E}bola virus infection : review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials},
  author = {{M}adelain, {V}. and {N}guyen, {T}. {H}. {T}. and {O}livo, {A}. and de {L}amballerie, {X}avier and {G}uedj, {J}. and {T}aburet, {A}. {M}. and {M}entre, {F}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he 2014-2015 outbreak of {E}bola virus disease is the largest epidemic to date in terms of the number of cases, deaths, and affected areas. {I}n {O}ctober 2015, no antiviral agents had proven antiviral efficacy in patients. {H}owever, in {S}eptember 2014, the {W}orld {H}ealth {O}rganization inventoried and has since regularly updated a list of potential drug candidates with demonstrated antiviral efficacy in in vitro or animal models. {T}his includes agents belonging to various therapeutic classes, namely direct antiviral agents (favipiravir and {BCX}4430), a combination of antibodies ({ZM}app), type {I} interferons, {RNA} interference-based drugs ({TKM}-{E}bola and {AVI}-7537), and anticoagulant drugs (r{NAP}c2). {H}ere, we review the pharmacokinetic and pharmacodynamic information presently available for these drugs, using data obtained in healthy volunteers for pharmacokinetics and data obtained in human clinical trials or animal models for pharmacodynamics. {F}uture studies evaluating these drugs in clinical trials are critical to confirm their efficacy in humans, propose appropriate doses, and evaluate the possibility of treatment combinations.},
  keywords = {{AFRIQUE} {DE} {L}'{OUEST}},
  booktitle = {},
  journal = {{C}linical {P}harmacokinetics},
  volume = {55},
  numero = {8},
  pages = {907--923},
  ISSN = {0312-5963},
  year = {2016},
  DOI = {10.1007/s40262-015-0364-1},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00014891},
}